(EGFR) revealed its predominantly membranous staining in 38 tumours with staining of 40–80% of the component cells. In addition, no differences in survival time between patients with different grades of EGFR reactivity when tumours with more than 50% of immunostained cells when compared with those with less then 50% or absence of expression. The gene discussed is EGFR; the disease is neoplasm.